ReviewDrugs2022
Atogepant: First Approval.
Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Oral preventive medications for migraine in adults aged 18-65: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.The journal of headache and pain · 2022Pooled it
- 2-Chloro-5-(trifluoromethyl)aniline-Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment.ChemistryOpen · 2026Article
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.Neurology and therapy · 2026Article
- Observational
- Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine.Pain and therapy · 2025Review
- Gepants: targeting the CGRP pathway for migraine relief.Frontiers in pharmacology · 2025Review
- Unmet Needs in the Acute Treatment of Migraine.Advances in therapy · 2024Article
- Atogepant: Mechanism of action, clinical and translational science.Clinical and translational science · 2024Review
- Research Progress in Calcitonin Gene-Related Peptide and Bone Repair.Biomolecules · 2023Review
- [Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans].Revista de neurologia · 2023Review
- FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022.International journal of molecular sciences · 2023Review
- Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode.ACS medicinal chemistry letters · 2022Article
- Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care.British journal of pain · 2022Article
- Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.Neurology and therapy · 2022Article
- The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.Therapeutics and clinical risk management · 2022Review
- Article
- Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.